• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Manhattan Pharmaceuticals, Inc. Presents Oleoyl Estrone Pharmacology Data at the North American Association for the Study of Obesity 2004 Annual Meeting

Posted on: Tuesday, 16 November 2004, 09:00 CST

Manhattan Pharmaceuticals, Inc. ("Manhattan" OTCBB: MHTT), will present the Company's latest pharmacology data related to their Oleoyl Estrone (OE) development program today, at 12:30 P.M. MST, at the North American Association for the Study of Obesity (NAASO) 2004 Annual Scientific Meeting in Las Vegas, NV.

In a poster presentation (#538-P) entitled, "Pilot Pharmacokinetic Study of Oleoyl Estrone Following a Single Oral Administration in Rats", Company scientists will discuss findings related to OE's uptake and distribution profile following oral administration. In a Company sponsored study, liquid chromatography tandem mass spectrometry (LS/MS/MS) was used to determine that natural levels in pre-dose rat plasma are in the range of 5 ng/mL. Uptake into blood could be detected within minutes following oral dosing, resulting in dose-related increases in OE plasma concentration which last for hours. Even at the highest dose levels administered (50 mg/kg), blood levels resulting from single doses of OE fell to background levels within 24 hours.

"This study, together with several others that we've recently completed, have been very useful in guiding the design of our imminent human trials," observed Dr. Leonard Firestone, Manhattan's Chief Executive Officer and President. "These data also underscore OE's natural presence in our blood, which we believe will lead to a safer, better tolerated obesity therapeutic."

Other studies featuring OE to be presented at the NAASO meeting include: (Poster 437-P) "Additive Effects of Combined Treatment of Overweight Rats With OE, and Dexfenfluramine, Sibutramine or Phentermine"; and, (Poster 436-P) "Additive Effects of OE and Beta-3 Adrenergic Agonist on Rat Body Energy."

In November 2003, the Manhattan announced the first, peer reviewed publication reporting human physiologic responses to OE, including marked weight loss, during 27 months of oral administration. More recently Manhattan scientists reported favorable preclinical toxicology data for OE at the 13th Annual Meeting of the European Congress on Obesity in May 2004.

About Oleoyl estrone

Oleoyl estrone is Manhattan Pharmaceuticals, Inc.'s lead product candidate. It is an orally administered small molecule shown to cause significant weight loss without the need for dietary modifications, in extensive preclinical animal studies. In such studies, OE appears to be safe and effective with no evidence of rebound weight gain after treatment has been discontinued. OE may prove to be a safe and effective treatment for obesity, representing a significant advantage over currently available anti-obesity medications.

About Manhattan Pharmaceuticals, Inc.

Manhattan Pharmaceuticals, Inc. (http://www.manhattanpharma.com/), a development stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the Company is developing Oleoyl estrone, an orally administered novel therapeutic for weight loss. To meet the needs of other major, underserved medical markets, while lowering development risks, Manhattan Pharmaceuticals also combines FDA-approved drugs with novel delivery technologies and formulations. The Company is developing a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures.

Certain statements contained in this news release that are forward-looking in nature are based on the current beliefs and assumptions of our management. When used in this press release, the words "may,""could,""should,""anticipate,""believe,""estimate,""expect,""intend,""plan,""predict," and similar expressions and their variants may be used to identify forward-looking statements. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission

Source: Business Wire

More News in this Category